B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

11.91 -0.70 (-5.55%)
Delayed Quote Updated: 11:21 AM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform ↗
Arcturus Therapeutics (NASDAQ:ARCT) presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to... 
Via MarketBeat
News headline image
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2026 Results: Revenue Miss Weighs on Sentiment as Pipeline Advances ↗
Via Chartmill
Arcturus Therapeutics (NASDAQ:ARCT) Stock Falls After Q4 2025 Revenue Miss ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Arcturus (ARCT) Q2 2026 Earnings Call Transcript ↗
Regaining vaccine rights and advancing rare disease programs toward key 2026 milestones. 
Via The Motley Fool
Topics Earnings
News headline image
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline ↗
Arcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is... 
Via MarketBeat
News headline image
Arcturus Therapeutics Q2 Earnings Call Highlights ↗
Arcturus Therapeutics (NASDAQ:ARCT) reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase... 
Via MarketBeat
Topics Earnings
News headline image
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies ↗
Arcturus Therapeutics (NASDAQ:ARCT) President and CEO Joseph Payne outlined the company’s messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the... 
Via MarketBeat
News headline image
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus (ARCT) Q1 2026 Earnings Call Transcript ↗
Arcturus (ARCT) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
Via Investor Brand Network
Topics Artificial Intelligence
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
Via Investor Brand Network
News headline image
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
From BioMedWire
Via GlobeNewswire
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The widely followed investor has been buying stocks trading well below their all-time highs. 
Via The Motley Fool
News headline image
These Are the Only 3 Stocks That Cathie Wood Bought Last Week ↗
The growing investing icon was skimpy on her purchases last week, making the names she did buy that much more interesting. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus (ARCT) Q4 2025 Earnings Call Transcript ↗
Arcturus (ARCT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Lawsuit
News headline image
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.